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Abstract
Background: When a medicine such as rofecoxib (Vioxx) is withdrawn, or a whole class of medicines discredited
such as the selective COX-2 inhibitors (COX-2s), follow-up of impacts at consumer level can be difficult and costly.
The Australian Longitudinal Study on Women’s Health provides a rare opportunity to examine individual consumer
medicine use following a major discrediting event, the withdrawal of rofecoxib and issuing of safety warnings on
the COX-2 class of medicines. The overall objective of this paper was to examine the impact of this discrediting
event on dispensing of the COX-2 class of medicines, by describing medicine switching behaviours of older
Australian women using rofecoxib in September 2004; the uptake of other COX-2s; and the characteristics of
women who continued using a COX-2.
Methods: Participants were concessional beneficiary status women from the Older cohort (born 1921-26) of the
Australian Longitudinal Study on Women’s Health who consented to linkage to Pharmaceutical Benefits Scheme
data, with at least one rofecoxib prescription dispensed in the 12 months before rofecoxib withdrawal. A
prescription was defined as one dispensing occasion. Women were grouped by rofecoxib pattern of use:
continuous (nine or more prescriptions dispensed in the 12 months prior to rofecoxib withdrawal) or non-
continuous (eight or less prescriptions dispensed in the 12 months prior to rofecoxib withdrawal) users. Incidence
rate per 100,000 person days and incidence risk ratio described uptake of alternate medicines, following rofecoxib
withdrawal. Kaplan-Meier curves described differences in uptake patterns by medicine and pattern of rofecoxib use.
Patterns of use of COX-2s in the next 100 days after first COX-2 uptake were described.
Results: Medicine switches and pattern of medicines uptake differed significantly depending upon whether a
woman was a continuous or non-continuous rofecoxib user prior to rofecoxib discrediting. Continuous rofecoxib
users overwhelmingly switched to another COX-2 and remained continuing COX-2 users for at least 100 days post-
switch.
Conclusions: The typical switching behaviour of this group of women suggests that the issues leading to the
discrediting of rofecoxib were not seen as a COX-2 class effect by prescribers to this high use group of consumers.
Background
NSAIDs (Non-Steroidal Anti-inflammatory Drugs)have
been consistently associated with adverse gastrointestinal
(GI) and renal effects [1]. Selective COX-2 inhibitors
(COX-2s) that promised to minimize adverse GI effects
[1] were first marketed in Australia in 1998, and listed on
the national medicines subsidy Pharmaceutical Benefits
Scheme (PBS) from 2000. While PBS guidelines suggested
that COX-2s should be prescribed only to patients with a
history of GI disorders, concomitant use of corticosteroids,
anti-coagulants and advanced age, rather than as routine
therapy [2], prescriptions for COX-2s increased rapidly,
peaking at about 250,000 Australian users in 2004 [3,4],
suggesting these guidelines were not being followed.
The expected advantage of fewer GI side effects for
COX-2s compared to non-selective NSAIDs (ns-NSAIDs)
was supported by longer-term safety studies, but early stu-
dies also showed an increase in cardiovascular (CVD) and
renal events [5,6]. Subsequent studies found a fourfold
increase in risk of myocardial infarction (MI) for rofecoxib
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[7], an excess of CVD events in trials of COX-2 efficacy in
preventing recurrent colonic polyps [8,9], and a greater
risk of coronary heart disease for high-dose rofecoxib
(> 25 mg/day) users in observational studies [10]. Safety
concerns intensified and rofecoxib was withdrawn by the
manufacturer world-wide in September 2004 [11,12].
While similar concerns were expressed in relation to other
COX-2s [13], these medicines were not withdrawn. In
Australia, the Therapeutic Goods Administration (TGA)
required manufacturers to provide explicit product infor-
mation warnings about CVD risk and advised that all
medicines in the COX-2s class should be regarded as hav-
ing increased CVD risk [14]. Regardless, two COX-2s, cel-
ecoxib and meloxicam, were both among the top 25
highest volume medicines dispensed on the PBS in 2006
[15]. In 2007, the TGA cancelled registration of lumira-
coxib, a newly available COX-2, due to concerns about
serious liver side effects, further discrediting this drug
class [16]. After the withdrawal of rofecoxib, paracetamol
(acetaminophen) was widely promoted as first line ther-
apy, especially for older people with arthritis [17], given
that ns-NSAIDs have also been associated with increased
CVD risk [18-20].
International examination of the context of the discre-
diting of the COX-2s and subsequent effects on prescrib-
ing practices have shown different medicine switching
patterns according to country differences in prescriber
characteristics, professional recommendations and thera-
peutic guidelines [5,21-30].
Longitudinal evaluation of a US pharmacy claims data-
base found increased prescribing of other NSAIDs,
including those with relative COX-2 selectivity, after the
withdrawal of rofecoxib and another COX-2, valdecoxib
[24]. A large US nationally representative cross-sectional
survey of ambulatory care visits showed relatively stable
NSAIDs prescribing from 1999 to 2005; initially, COX-2s
substituted ns-NSAIDs, but after withdrawal of rofecoxib,
prescribing of ns-NSAIDs and non-narcotic analgesics
rose sharply [28], suggesting the perception of a class
effect.
In the UK, data from the General Practice Research
Database showed that approximately 80% of those using
COX-2s stopped within 6 months of the major discredit-
ing event (the withdrawal of rofecoxib) [27]. In Scotland,
data from a national prescription database showed that
the withdrawal of rofecoxib led to a short-lived initial
increase in prescription of celecoxib, and a parallel
increase in the prescription of other NSAIDs, suggesting
these were prescribed as alternatives to rofecoxib [21]. In
Ireland, interrogation of a national prescribing database
found prescribers were less likely to switch patients pre-
viously receiving rofecoxib therapy to another COX-2
irrespective of age or gender, either in the short or longer
term [23]. The authors suggest that prescribers viewed
rofecoxib related CVD safety concerns as a class effect
[30]. However, another Irish study found evidence of
chronic use of COX-2s despite discrediting [22], with
female patients, those over 65 years and those at CVD
risk more likely to start celecoxib rather than a ns-
NSAID, suggesting that prescribers may not have per-
ceived the discrediting as a class effect [22,30]. Other
European studies had varying findings. A small Italian
study found that rofecoxib withdrawal resulted in a
marked decrease of COX-2 use in general practice, indi-
cative of a belief in a class effect [26]. In contrast, a Ger-
man study, using data for patients within the statutory
health insurance system [29], rofecoxib withdrawal led to
initial increased prescribing of other COX-2s (celecoxib,
valdecoxib), similar to the situation in Scotland [21]. Sub-
sequent safety warnings on COX-2s and the withdrawal
of valdecoxib in April 2005 led to pronounced reductions
in COX-2 prescribing, and increased ns-NSAID prescrib-
ing. While German physicians responded promptly to
safety warnings [29], reduced prescribing of COX-2s led
to a simultaneous increase in NSAID prescribing, and
especially those NSAIDs with a relative preference for
COX-2, which may be associated with COX-2 like safety
risks [29]. In the Netherlands, a study of individual pre-
scription patterns of COX-2 users showed that while dis-
crediting led to a significant decrease in use of COX-2s,
large numbers of patients appeared not to switch to alter-
native pain treatments [25].
In Australia, aggregated PBS dispensing data have been
used to examine the influence of COX-2s on overall
NSAIDs and paracetamol prescribing afterCOX-2 discre-
diting [2]. Overall NSAIDs use declined, with evidence of
slight increases in the use of paracetamol in April 2005.
Reduced total COX-2 prescribing following rofecoxib
withdrawal suggested prescribers saw discrediting as a
class effect. While these aggregated data show the rise and
fall of COX-2 prescribing in Australia, individual switching
behavior can only be assumed, given the lack of examina-
tion of individual level longitudinal data. A study of COX-
2 use in an Australian veteran population [5], found that
despite the increased vulnerability of veterans receiving
heart failure or diabetes medicines to adverse NSAIDs
effects, uptake rates of COX-2s were similar to the rest of
the veteran population, suggesting that while GI safety
messages were interpreted broadly by prescribers, other
adverse effects were not considered [5]. No Australian stu-
dies have evaluated the effects of COX-2 discrediting on
individual level patterns of medicine use for a large general
population sample [4].
When a medicine is withdrawn, as in the case of rofe-
coxib, follow-up at the individual consumer level is uncom-
mon, as it can be difficult and costly. The Australian
Longitudinal Study on Women’s Health (ALSWH) provides
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behaviours following a discrediting event in a large cohort
of older women. The overall objective of this paper was to
examine the impact of the major COX-2 discrediting event
(withdrawal of rofecoxib) on dispensing of the COX-2 class
of medicines. The specific aims were to describe:
1. medicine switching after rofecoxib withdrawal by
older Australian women using rofecoxib at30 September
2004;
2. characteristics of women who switched to an alter-
nate COX-2 in the first 100 days after 30 September
2004; and
3. patterns of use of alternate COX-2s taken up in the
first 100 days after rofecoxib withdrawal, in the next 100
days after this medicine switch.
Methods
Data for this project are from Australian Longitudinal
Study on Women’s Health (ALSWH) Surveys 3 (S3) and 4
(S4) for the 1921-26 birth year cohort(undertaken 2002
and 2005), individually linked to PBS medicines data. The
ALSWH is a national study which began in 1996 with a
random sample of more than 40,000 women in three age
cohorts [31]. Since 1998, follow-up surveys have occurred
on a three yearly staggered cycle by age cohort. The Older
cohort of women (n = 12,432) were 70-75 years at S1 in
1996 and 79-84 years at S4 (distributed March 2005, after
discrediting). Retention rates over the 10 years of the
study have been high (over 80% at each survey). Further
information about ALSWH can be found at http://www.
alswh.org.au[32]. The University of Newcastle Human
Research Ethics Committee approved all aspects of the
study (H-076-0795).
ALSWH self-report survey data
The following ALSWH self-report survey variables were
considered: Area of residence: urban vs. non-urban [33];
Ease of managing on income. impossible/difficult all of
the time/difficult some of the time, vs. not too bad/easy;
Education. no school qualifications, vs. school/higher qua-
lifications; Marital status: married/living as married, vs.
separated/divorced, vs. widowed/single; WHO Body Mass
Index (BMI) [34]: Underweight (BMI < 18.5), vs. normal
(BMI = 18.5 - 24.99), vs. overweight and obese (BMI ≥
25.0); Smoker: yes, vs. no; Alcohol use: non-drinker, vs.
rarely/low risk drinker, vs. risky/high risk; General health:
excellent/very good/good, vs. fair/poor; Family Doctor
visits in 12 months.0 - 4 ,v s .5 +v i s i t s ;Other specialist
doctor visit in 12 months.Y e s ,v s .n o ;Hospital doctor
visit in 12 months.Yes, vs. no; Self-reported conditions:
Yes to: Arthritis (any type), Hypertension, Depression,
Anxiety/Nervous, Asthma, Diabetes, Bronchitis/Emphy-
sema, Osteoporosis, Heart Disease, Cancer diagnosed or
treated in past three years?
Pharmaceutical Benefits Scheme (PBS)medicines data
Medicare Australia collates records of prescriptions subsi-
dised under the national PBS (including the Repatriation
Pharmaceutical Benefits Scheme). These administrative
data provide information about medicine item number,
description, dispensing dates, costs and patient beneficiary
status. Consent for linkage of PBS data was obtained from
68% of the Older cohort, with few differences between
those who did and did not provide consent [35]. Details of
methods used to request consent have been reported else-
where [36]. PBS data were linked at the individual level to
ALSWH survey data from 2002 to 2007.
PBS data will not include all medicines taken, particu-
larly those that are purchased over the counter, provided
in hospital, or purchased without subsidy [37]. A particular
issue is that medicines costing less than the consumer
“copayment” will not be captured [38]. For example, the
copayment for general beneficiaries in 2002 was AUD
(Australian dollars)22.40 (equivalent to USD (US dollars)
40) [39], and therefore only dispensing for medicines cost-
ing more than this amount will be recorded in the PBS
datasets. Where medicines of interest do fall under the
copayment amount, analyses can be limited to conces-
sional beneficiaries who pay a nominal copayment fee (e.g.
AUD3.60 or USD6.43 in 2002) and for whom data capture
will be complete [39].
Medicines were coded to conform to the Anatomical
Therapeutic Chemical Code, to facilitate analysis [40]. The
medicine groups of interest for this study were: COX-2s
(including rofecoxib, celecoxib, lumiracoxib, meloxicam),
ns-NSAIDs (including diclofenac, ibuprofen, naproxen,
acetylsalicylic acid, piroxicam), opioids, and paracetamol
(also known as acetaminophen) and combinations, defined
with reference to Australian Medicines Handbook [41].
Analyses
Women included in analyses had consented to the release
of their PBS data and had a status of “concessional benefi-
ciary” within the PBS for the entire period of follow up, as
many of the medicines of interest were under copayment
(as described above) for at least some of the study period.
This represented 85% of the Older cohort who consented
to PBS linkage.
The date of withdrawal of rofecoxib, 30 September
2004, was the start date for follow-up of medicine switch-
ing, and 31 December 2007 was the end date. Women
were included only if they had at least one rofecoxib pre-
scription dispensed in the 12 months prior to rofecoxib
withdrawal (that is, 30 September 2003 to 30 September
2004), and had a minimum of 12 months follow-up (until
30 September 2005). A prescription was defined as one
dispensing occasion. Each prescription for rofecoxib con-
tained 30 tablets. Given it was expected that the switch-
ing behaviour of those with higher expressed need for
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more frequently) may be different from the behaviour of
those with less need, two groups of rofecoxib users were
characterized, based on number of rofecoxib prescrip-
tions dispensed [42]:
Continuous Users(index group for the purposes of the
analysis): Nine or more rofecoxib prescriptions dis-
pensed in the 12 months before discrediting (30 Sep-
tember 2003 to 30 September2004). This represents 75%
or more of fulltime therapy.
Non-Continuous Users(reference group): Eight or fewer
rofecoxib prescriptions dispensed in the 12 months before
discrediting. (See Figure 1). This non-continuous users
group would be expected to have more heterogeneous
prescription patterns than the continuous users group,
with patterns potentially ranging from one prescription (at
either end of the 12 months period), to regular prescrip-
tions over the 12 months of interest. Median number of
rofecoxib prescriptions and interquartile range was calcu-
lated for each rofecoxib user group.
The incidence rate for uptake of an alternate medi-
cine (switching) for each rofecoxib user group was cal-
culated as the number of incident cases divided by the
total number of participant days [42,43]. Number of
participant days was measured from starting date (30
September 2004) until either first prescription for the
alternate medicine, the last known date of the woman
in the database or the end of the study period (31
December 2007), whichever came first. Incidence risk
ratios (IRR) and 95% confidence intervals (CI) were
calculated for rofecoxib continuous (index) and rofe-
coxib non-continuous (reference) groups. Alternate
medicines for rofecoxib included in these analyses were
other COX-2s, ns-NSAIDs, opioids, paracetamol and
paracetamol combinations, decided from formative
analyses of switching behaviours (data not presented).
Only women who had not been dispensed a prescrip-
tion for the relevant alternate medicine within the 12
months before rofecoxib withdrawal were counted in
the incidence rate. Kaplan-Meier curves were con-
structed for all medicines and significance determined
using the log-rank test (p < 0.05). Only the graphs for
the most common medicines switched to (meloxicam,
celecoxib, and paracetamol/paracetamol combinations)
are presented in this paper.
Women were further characterised as COX-2 switchers
(i.e. switched to another COX-2 within 100 days after rofe-
coxib withdrawal) and COX-2 stoppers (did not switch to
another COX-2 within 100 days after withdrawal of rofe-
coxib). The pattern of COX-2 use was further described
for COX-2 switchers for the first 100 days after switching
to the alternate COX-2. A continuing COX-2 user was
defined as having been dispensed another two or more
COX-2 prescriptions in the first 100 days after first pre-
scription for an alternate COX-2 (that is, at least three
prescriptions in 100 days including first prescription).
ALSWH survey demographic, health behaviour and
health service use characteristics were compared for con-
tinuous rofecoxib users versus non-continuous rofecoxib
users, and for COX-2 switchersversusCOX-2 stoppers,
using chi square and Fishers exact tests. A conservative
alpha value of 0.005 was used, due to the risk of Type1
error due to multiple comparisons. All analyses were
undertaken using SAS statistical software (version 9.2)
[44].
Results
Participants
The sample comprised 564 women including 181(33%)
continuous rofecoxib users in the 12 months prior to rofe-
coxib withdrawal. The median number of rofecoxib pre-
scriptions dispensed for continuous users was 11 (IQR: Q1
= 10; Q3 = 12), and 2 prescriptions (IQR: Q1 = 1; Q3 = 4)
for non-continuous users. (See Figure 1).
In Table 1, continuous rofecoxib users, in the 12
months prior to rofecoxib withdrawal, were significantly
more likely to report having ever been diagnosed with
arthritis than were non-continuous users (94% com-
pared to 75%, p < 0.001).
1921-26 Cohort 
PBS Consenters (n=5484) 
Concessional Beneficiaries (n=4427) 
Rofecoxib Users (n=564) 
Continuous Users 
(> 9 prescriptions) 
(n=181) 
Median number = 11 
(IQR: 10-12) 
Non-Continuous Users 
(< 9 prescriptions) 
(n=383) 
Median number = 2 
(IQR: 1-4) 
Figure 1 Sample selection for ALSWH Older cohort.
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Continuous rofecoxib users were significantly more
likely to switch to another COX-2 (IRR = 4.6; 95%CI:
3.6-5.9) or to a paracetamol based medicine (IRR = 1.8;
95%CI 1.3-2.5) than were non-continuous rofecoxib
users (See Table 2).
The Kaplan-Meier curves for uptake of meloxicam,
celecoxib, and paracetamol show significantly different
uptake patterns for continuous rofecoxib users com-
pared to non-continuous rofecoxib users for all these
medicines. At 100 days after discrediting, 44% of contin-
uous users and 15% of non-continuous users had
switched to meloxicam; 28% of continuous users and 9%
of non-continuous users had switched to celecoxib (See
Figures 2 and 3); while24% of continuous users and 15%
of non-continuous users had taken up paracetamol/
paracetamol combinations at 100 days after rofecoxib
withdrawal (See Figure 4). At 200 days after rofecoxib
discrediting, 49% of continuous users and 18% of non-
continuous users had switched to meloxicam; 30% of
continuous users and 10% of non-continuous users had
switched to celecoxib, only small increases in uptake for
both COX-2s compared to the 100 day levels. However,
33% of continuous users and 21% of non-continuous
users had taken up paracetamol/paracetamol combina-
tions at 200 days (increases of 9% and 6%), showing that
uptake of paracetamol based medicines was more sus-
tained over time than for the COX-2s.
Table 1 Characteristics of non-continuous and continuous rofecoxib users (in the 12 months prior to rofecoxib
withdrawal)
Characteristic
c Non-Continuous rofecoxib users
a
(N = 383)
%
Continuous rofecoxib users
b
(N = 181)
%
Χ
2, df, p-value
Urban Area 51 50 0.06, 1, 0.81
Manage on Income 81 75 2.96, 1, 0.09
Education (No School) 73 71 0.12, 1, 0.73
Marital Married/De facto 34 35
Sep/Divorced 4 6 1.81, 2, 0.40
Widowed/Single 56 59
BMI Underweight 2 1
Normal 47 43 0.043
d
O/weight 50 56
Smoker 4 6 0.89, 1, 0.34
Alcohol Non-drinker 69 59
Rarely/Low drinker 30 34 0.24
d
Risky/High Risk 1 7
Exc/V. Good/Good General Health 62 59 0.29, 1, 0.59
Consulted Family Doctor ≥5 Visits 73 77 0.94, 1, 0.33
Hospital Doctor Visit in 12 months 22 24 0.35, 1, 0.56
Specialist Doctor Visit in 12 months 61 51 4.73, 1, 0.03
Ever Reported Arthritis 75 94 31.02, 1, < 0.001
Conditions: Hypertension 45 38 2.62, 1, 0.11
Depression 6 9 1.14, 1, 0.28
Anxiety/nervous 7 8 0.18, 1, 0.68
Asthma 8 14 3.99, 1, 0.05
Diabetes 11 15 1.55, 1, 0.21
Bronchitis/Emphysema 6 9 1.92, 1, 0.17
Osteoporosis 29 34 1.35, 1, 0.25
Heart Disease 21 30 5.23, 1, 0.02
Cancer 6 4 0.96, 1, 0.33
a Eight or fewer rofecoxib prescriptions dispensed in 12 months before rofecoxib withdrawal (30 September 2003 to 30 September 2004)
b Nine or more rofecoxib prescriptions dispensed in 12 months before rofecoxib withdrawal
c See methods for details of these self-reported ALSWH variables
d Fisher’s exact test used due to small cell sizes, p-value only reported
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stoppers
Women who took up another COX-2(COX-2 switchers)
were significantly more likely to have been a continuous
rofecoxib user (47% compared to 14%, p < 0.0001), and
to have a diagnosis of arthritis (86% compared to 77%, p
= 0.003), than were COX-2 stoppers. (See Table 3).
Medicine use by COX-2 switchers in the next 100 days
after switching
In the first 100 days after rofecoxib discrediting, 189
women switched to another COX-2. Of the 108 women
who switched to meloxicam, 64 had been continuous rofe-
coxib users and 52 became continuing COX-2 users for at
least 100 days; 8 of the 44 non-continuous rofecoxib users
became continuing COX-2 users. Of the 81 women who
switched to celecoxib, 50 had been continuous rofecoxib
users and 32 maintained continuing COX-2 use for at least
100 days; 31 had been non-continuous rofecoxib users, and
11 became continuing COX-2 users (See Figure 5).
Discussion
This study explored individual patterns of medicine use
and characteristics of COX-2 users following the
Table 2 Population at risk (N), incident cases, incidence rate and IRR, by medicine and rofecoxib user status, for
ALSWH Older cohort
Continuous Users Non-Continuous Users IRR (95%
CI)
Medicine N
a Cases Incidence rate (per 100,000
person days)
N
a Cases Incidence rate (per 100,000
person days)
COX-2s Overall 163 130 272.2 320 146 58.8 4.6
(3.6,5.9)
Celecoxib 163 59 44.9 320 54 16.7 2.7 (1.8,4)
Lumiracoxib 163 12 6.7 320 17 4.7 1.4
(0.6,3.2)
Meloxicam 163 98 111.3 320 100 34.8 3.2
(2.4,4.3)
ns-NSAIDs Overall 137 56 47.9 274 101 40.7 1.2
(0.8,1.6)
Diclofenac 137 14 9.6 274 24 8.0 1.2
(0.6,2.4)
Ibuprofen 137 10 6.6 274 15 4.9 1.4
(0.5,3.2)
Naproxen 137 10 6.6 274 8 2.6 2.6
(0.9,7.5)
Piroxicam 137 43 33.2 274 95 37.9 0.9
(0.6,1.3)
Acetylsalicylic acid 137 4 2.6 274 3 1.0 2.7
(0.5,18.4)
Other ns-NSAIDs 137 5 3.2 274 9 2.9 1.1
(0.3,3.7)
Opioids Overall 143 45 32.5 321 86 26.7 1.2
(0.8,1.8)
Buprenorphine 143 5 3.0 321 12 3.2 0.9
(0.3,2.9)
Morphine 143 5 3.0 321 19 5.1 0.6
(0.2,1.6)
Oxycodone 143 15 9.3 321 33 9.2 1 (0.5,1.9)
Tramadol 143 36 25.5 321 52 15.5 1.7 (1,2.6)
Other Opioids 143 2 1.2 321 4 1.1 1.1
(0.1,7.9)
Paracetamol Overall 71 56 138.0 171 96 76.6 1.8
(1.3,2.5)
Paracetamol and combinations excl.
psycholeptics
71 56 138.0 171 96 76.4 1.8
(1.3,2.5)
Codeine, combinations excl.
psycholeptics
71 3 3.7 171 6 3.1 1.2
(0.2,5.6)
a Includes only women not dispensed these medicines in the 12 months prior to rofecoxib withdrawal
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women with a “concessional beneficiary” status in a
national general population sample of older Australian
women. The type of medicine switched to and the pat-
tern of medicine use differed significantly depending
upon whether a woman was a continuous(high use) or
non-continuous (lower use) rofecoxib user in the 12
months prior to the discrediting event. Continuous users
overwhelmingly switched to another COX-2 and
remained a continuing COX-2 user for at least 100 days
post-switch. The switching behaviour observed here sug-
gests that the safety issues leading to the discrediting of
rofecoxib may not have been seen as a COX-2 class effect
by this group of Australian prescribers and consumers.
Although there has already been considerable explora-
tion of this discrediting event [2,21-24,26-29], the
strength and interest of this study is that it examines
medicine use at the individual consumer level. The link-
age of national subsidised pharmaceutical database medi-
cines data to longitudinal survey data avoids the issues of
consumer recall and allows examination of dispensing
patterns in relation to the demographic, health and
health service use characteristics of consumers. This
study is novel in Australia.
There are some limitations to the study. First, the cohort
includes only women. However, prevalence of arthritis is
s i g n i f i c a n t l yh i g h e rf o rw o m e nt h a nf o rm e ni nt h eU S A
[45], Canada [46], the UK [47], and Australia [48,49], so
this is an appropriate group in which to study the use of
arthritis medicines. Second, many of the alternate medi-
cines cost less than the PBS general copayment for at least
some of the study period, meaning that only women with
a “concessional beneficiary” P B Ss t a t u sf o ra l ly e a r so f
interest could be included. This represents 85% of the
Older ALSWH cohort who agreed to PBS linkage. Pre-
vious analyses have found that Older ALSWH conces-
sional women were quite similar to non-concessional
Older ALSWH women - although less likely to see a spe-
cialist or be overweight and more likely to have hyperten-
sion [35]. A third issue is that the PBS does not capture
over-the-counter analgesics, so use of these medicines
may be underestimated. However, in other research,
where PBS data was compared with medicines data col-
lected from a home visit medicine audit for people aged
65 years and over, PBS data was found to be close to com-
plete, so we might expect the same for this group of con-
cessional status older women [50]. A fourth issue is that
the patterns of prescriptions for the non-continuous users
group, included as a comparator for the continuous users
(Log-rank Test: <0.0001)
Figure 2 Time to first meloxicam prescription uptake for
continuous and non-continuous users.
(Log-rank Test: <0.0001)
Figure 3 Time to first celecoxib prescription uptake for
continuous and non-continuous users.
(Log-rank Test: 0.001) 
Figure 4 Time to first paracetamol (combined)prescription
uptake for continuous and non-continuous users.
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neous than for the continuous users group. The non-con-
tinuous users group is defined as women dispensed eight
or fewer rofecoxib prescriptions in the 12 months before
discrediting, on the premise that these women had a lesser
expressed need for these medicines. So, this group could
potentially include women who received only one pre-
scription early in the 12 months (where the discrediting
event was unlikely to be an issue), or one prescription late
in the 12 months, or regular prescriptions over the 12
months of interest. The median number of scripts in this
group is two prescriptions (IQR: 1-4) in 12 months, so
there would be few women who received regular prescrip-
tions, but time of dispensing could be quite varied. This
means that interpretation of behaviour for this group must
be circumspect, and may not necessarily be closely tied to
the discrediting event. This group is useful, however, as a
comparator for the switching behaviour of continuous
users.
The patterns of medicine switching varied significantly
depending upon whether a woman was a continuous or
non-continuous rofecoxib user pre-discrediting. Contin-
uous rofecoxib users overwhelmingly switched to
another COX-2, mostly within 100 days of rofecoxib
withdrawal, and the majority remained continuing
COX-2 users for at least another 100 days. When an
alternate COX-2 was not taken up in the first 100 days
by erstwhile continuous rofecoxib users, they were less
likely to be taken up over the 1200 days of the study.
Interestingly, a significant proportion (24%) of non-
Table 3 Demographic, health, and health care use characteristics of COX-2 switchers and COX-2 stoppers in the first
100 days after discrediting of rofecoxib
Characteristic COX-2 Switchers
a (N = 189)
%
COX-2 Stoppers
a
(N = 81)
%
c
2, df, p-value
Continuous Rofecoxib User 47 14 61.90, 1, < 0.0001
Urban Area 57 45 7.54, 1, 0.01
Able to Manage on Income 80 78 0.47, 1, 0.49
No Formal Education 72 73 0.03, 1, 0.87
Marital Married/De facto 40 36
Sep/Divorced 4 6 2.29, 1, 0.32
Widowed/Single 56 58
BMI Underweight 1 3
Normal 44 48 0.02
b
O/weight 55 49
Alcohol Non-drinker 63 68
Rarely/Low drinker 32 31 0.05
b
Risky/High Risk 5 1
Smoker 4 5 0.77, 1, 0.38
Excellent/Very Good/Good General Health 63 59 0.60, 1, 0.44
Consulted Family Doctor ≥5 Visits 70 79 5.15, 1, 0.02
Hospital Doctor Visit in 12 months 19 26 3.36, 1, 0.07
Specialist Doctor Visit in 12 months 55 62 2.56, 1, 0.11
Conditions:
Ever Reported Arthritis 86 77 9.03, 1, 0.003
Hypertension 61 54 2.93, 1, 0.09
Depression 6 8 1.29, 1, 0.26
Anxiety/nervous 7 7 0.15, 1, 0.70
Asthma 9 11 0.24, 1, 0.62
Diabetes 14 11 0.93, 1, 0.33
Bronchitis/Emphysema 5 9 3.3, 1, 0.07
Heart Disease 21 27 2.16, 1, 0.14
Cancer 4 6 1.97, 1, 0.16
a In the first 100 days after rofecoxib discrediting
b Fisher’s exact test used due to small cell sizes, p-value only reported
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a. One or more rofecoxib prescriptions dispensed in 12 months before rofecoxib withdrawal (30 September 
2003 to 30 September 2004).
b.  First medicine switch within 100 days of rofecoxib withdrawal. 
c.  Nine or more rofecoxib prescriptions dispensed in 12 months before rofecoxib withdrawal.
d. Eight or less rofecoxib prescriptions dispensed in 12 months before rofecoxib withdrawal.
e. Two or more COX-2 prescriptions dispensed in 100 days from first COX-2 prescription after rofecoxib 
withdrawal.
1921-26 Cohort 
Concessional status women (n=4427) 
Rofecoxib Users
a (n=564) 
COX-2 Switchers (first switch within 
100 days of rofecoxib withdrawal) 
 (n=189) 
Switched to Meloxicam
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(n=108) 
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Figure 5 COX-2 use in the next 100 days after first COX-2 switch. a One or more rofecoxib prescriptions dispensed in 12 months before
rofecoxib withdrawal (30 September 2003 to 30 September 2004). b First medicine switch within 100 days of rofecoxib withdrawal. c Nine or
more rofecoxib prescriptions dispensed in 12 months before rofecoxib withdrawal. d Eight or less rofecoxib prescriptions dispensed in
12 months before rofecoxib withdrawal. e Two or more COX-2 prescriptions dispensed in 100 days from first COX-2 prescription after rofecoxib
withdrawal.
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Page 9 of 12continuous rofecoxib users also became continuing
COX-2 users for at least 100 days after first post-discre-
diting uptake; however a direct switch to another COX-
2 was much less common for this group of less frequent
rofecoxib users. It appears from these findings that rofe-
coxib discrediting was not seen as a class effect by many
prescribers to these women. This contrasts with the
findings of Barozzi & Tett who suggested that reduced
COX-2s prescribing following rofecoxib withdrawal con-
firmed prescribers saw the discrediting as a class effect
[2]. While this previous analysis showed that the rise
and fall of the COX-2s did markedly influence overall
NSAIDs prescribing in Australia, this was only at an
aggregate level, and individual switching behaviour
could only be assumed. As shown in the current study,
at the individual level, it may be that consumer charac-
teristics and preference played a part in the decision on
switching. Certainly, those who had previously been dis-
pensed rofecoxib less frequently before discrediting,
those who might be assumed to have a lesser need, were
less likely, then to take up another COX-2, but this was
not the case for those with higher expressed need, those
more frequently dispensed rofecoxib. In an aggregate
analysis, this detail can be lost, if there are considerably
fewer continuous than non-continuous users.
There were few individual characteristics associated
with early uptake of an alternate COX-2. COX-2 switch-
ers were more likely to have a diagnosis of arthritis and
to have been a continuous rofecoxib user than were
COX-2 stoppers, both these circumstances potentially
indicating women who experienced more persistent pain.
There is some evidence that consumer satisfaction with
the COX-2s is high [51], so women may have preferred
to stay with this drug class. Non-continuous users may
indeed have only used rofecoxib on very few occasions(as
evidenced by a median number of only two prescriptions
dispensed in 12 months), so rofecoxib withdrawal may
have had only minimal impact on their medicine use
behaviour.
There is general international clinical agreement that
paracetamol should be the pain killer of first choice for
arthritis, as a full therapeutic dose provides adequate
analgesia for many people, with less risk of side-effects or
interactions compared with NSAIDs and other analgesics
[2,3,52-54]. New PBS listings for paracetamol containing
preparations since April 2005 allow for use of higher doses
and quantities of paracetamol specifically for chronic
arthropathies and arthritis pain, with the intention of
encouraging use of appropriate, regular doses of paraceta-
mol [2]. In this study we found that continuous rofecoxib
users were more likely to switch to paracetamol than were
non-continuous users. Uptake of paracetamol was slower,
and more sustained, and given this slow uptake, the link
with the discrediting event m a yb es o m e w h a tt e n u o u s .
Again, the findings of Barozzi & Tett [2] that use of para-
cetamol was steady across 1997-2004 with a slight increase
in April 2005, can be contrasted with the current indivi-
dual level data, which provides the nuances available at
this level of data. (See Figure 4).
Conclusions
While the risk profile that lead to the withdrawal of rofe-
coxib might be indicative of aCOX-2 class effect
[11,19,55], this may not have been the understanding of
many prescribers (or consumers) for this group of com-
munity living older Australian women. This interpretation
of COX-2 class risk has also varied across international
studies of prescribing following the rofecoxib discrediting
event, with some studies demonstrating a prescriber
response to a class effect [2,23,26,28,30], and some not
[22,24,26]. Further research is appropriate to confirm our
findings, given this controversy. There is some evidence
for continuing chronic use of COX-2s despite discrediting
[22], and it would be of interest to explore if this is the
case for this group of women, and consider the potential
impact on longer term health outcomes.
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